Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of EUR 127.25 billion. The enterprise value is 141.66 billion.

Market Cap	127.25B
Enterprise Value	141.66B

Important Dates

The last earnings date was Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	Jun 13, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+0.68%
Shares Change (QoQ)	-0.32%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 23.68 and the forward PE ratio is 14.23.

PE Ratio	23.68
Forward PE	14.23
PS Ratio	5.18
PB Ratio	7.63
P/TBV Ratio	n/a
P/FCF Ratio	15.95
P/OCF Ratio	15.14
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.88, with an EV/FCF ratio of 17.76.

EV / Earnings	26.36
EV / Sales	5.75
EV / EBITDA	11.88
EV / EBIT	15.05
EV / FCF	17.76

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 1.27.

Current Ratio	1.32
Quick Ratio	0.97
Debt / Equity	1.27
Debt / EBITDA	1.79
Debt / FCF	2.66
Interest Coverage	11.04

Financial Efficiency

Return on equity (ROE) is 33.40% and return on invested capital (ROIC) is 16.02%.

Return on Equity (ROE)	33.40%
Return on Assets (ROA)	12.62%
Return on Invested Capital (ROIC)	16.02%
Return on Capital Employed (ROCE)	24.77%
Revenue Per Employee	1.40M
Profits Per Employee	305,330
Employee Count	17,600
Asset Turnover	0.53
Inventory Turnover	3.22

Taxes

In the past 12 months, Gilead Sciences has paid 757.84 million in taxes.

Income Tax	757.84M
Effective Tax Rate	12.36%

Stock Price Statistics

The stock price has increased by +52.59% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+52.59%
50-Day Moving Average	95.96
200-Day Moving Average	93.92
Relative Strength Index (RSI)	62.14
Average Volume (20 Days)	294

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.67

Income Statement

In the last 12 months, Gilead Sciences had revenue of EUR 24.58 billion and earned 5.37 billion in profits. Earnings per share was 4.27.

Revenue	24.58B
Gross Profit	19.30B
Operating Income	9.39B
Pretax Income	6.13B
Net Income	5.37B
EBITDA	11.75B
EBIT	9.39B
Earnings Per Share (EPS)	4.27

Full Income Statement

Balance Sheet

The company has 5.16 billion in cash and 21.24 billion in debt, giving a net cash position of -14.45 billion.

Cash & Cash Equivalents	5.16B
Total Debt	21.24B
Net Cash	-14.45B
Net Cash Per Share	n/a
Equity (Book Value)	16.68B
Book Value Per Share	13.49
Working Capital	3.00B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.40 billion and capital expenditures -424.90 million, giving a free cash flow of 7.98 billion.

Operating Cash Flow	8.40B
Capital Expenditures	-424.90M
Free Cash Flow	7.98B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.53%, with operating and profit margins of 38.22% and 21.87%.

Gross Margin	78.53%
Operating Margin	38.22%
Pretax Margin	24.95%
Profit Margin	21.87%
EBITDA Margin	47.82%
EBIT Margin	38.22%
FCF Margin	32.46%

Dividends & Yields

This stock pays an annual dividend of 2.84, which amounts to a dividend yield of 2.79%.

Dividend Per Share	2.84
Dividend Yield	2.79%
Dividend Growth (YoY)	1.05%
Years of Dividend Growth	10
Payout Ratio	62.75%
Buyback Yield	-0.68%
Shareholder Yield	2.11%
Earnings Yield	4.22%
FCF Yield	6.27%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 3.47 and a Piotroski F-Score of 7.

Altman Z-Score	3.47
Piotroski F-Score	7